Loading…
Based on limited metadata with no full letter text available, the FDA issued a warning letter to Guangdong Kemei Pharmaceutical Technology Co. Ltd., a pharmaceutical manufacturer, on December 14, 2021. While the specific violations are not detailed in the available metadata, the letter addresses concerns related to drug manufacturing or product quality. The warning falls under FDA's drug product regulatory authority, though the specific manufacturing deficiencies cannot be determined from the metadata provided.